No new quantitative data was released — the posters are incremental scientific updates. The next material catalyst for HLP003 will be Phase 3 PARADIGM topline data. Monitor for data readout timelines in future filings.
Price Chart
Executive Summary
Cybin Inc., operating as Helus Pharma, presented four posters at Psych Congress 2026 covering new analyses of HLP003, its investigational deuterated psilocin analog for major depressive disorder. The posters include 12-month efficacy data from a completed Phase 1/2a study and a trial-in-progress overview of the ongoing Phase 3 PARADIGM program. This is a routine scientific conference update with no new quantitative efficacy or safety results disclosed, making it a neutral clinical development milestone.
Key Facts
- Helus Pharma presented four posters on HLP003 at Psych Congress 2026 (Sept 15-19, New Orleans).
- Three posters build on the completed Phase 1/2a study of HLP003 for adjunctive MDD, including 12-month efficacy results.
- One poster provides a trial-in-progress overview of the ongoing Phase 3 PARADIGM program.
- HLP003 has Breakthrough Therapy Designation from the FDA.
- HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company.
Risk Factors
- Phase 3 PARADIGM trial may fail to meet endpoints, as is common in psychedelic-assisted therapy studies.
- Regulatory approval for HLP003 is not guaranteed despite Breakthrough Therapy Designation.
- Company is pre-revenue and will require additional capital to fund ongoing clinical programs.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001833141-26-000076 |
| Document: cybininc-form6xk09x21x2026.htm | 0001833141-26-000076 |
| Document: 0001833141-26-000076-index-headers.html | 0001833141-26-000076 |
| Document: 0001833141-26-000076-index.html | 0001833141-26-000076 |
| Document: 0001833141-26-000076.txt | 0001833141-26-000076 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $10.66 | awaiting T+20 | — | $10.52 (−1.27%) |
Oct 26, 2026 1d ago | 3 | $10.36 | awaiting T+20 | — | $10.52 (+1.54%) |
Oct 26, 2026 1d ago | 3 | $10.36 | awaiting T+20 | — | $10.52 (+1.54%) |
Oct 23, 2026 4d ago | 3 | $10.36 | awaiting T+20 | — | $10.52 (+1.54%) |
Oct 23, 2026 4d ago | 3 | $10.36 | awaiting T+20 | — | $10.52 (+1.54%) |
Oct 23, 2026 4d ago | 3 | $10.36 | awaiting T+20 | — | $10.52 (+1.54%) |
Oct 23, 2026 4d ago | 3 | $10.36 | awaiting T+20 | — | $10.52 (+1.54%) |
Oct 21, 2026 6d ago | 6-K | $10.50 | awaiting T+20 | — | $10.52 (+0.19%) |
Oct 15, 2026 12d ago | 6-K | $11.05 | awaiting T+20 | — | $10.52 (−4.80%) |
Oct 15, 2026 12d ago | Press Release | $11.05 | awaiting T+20 | — | $10.52 (−4.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers